<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="72574"><DrugName>cenerimod</DrugName><DrugNamesKey><Name id="43063360">cenerimod</Name></DrugNamesKey><DrugSynonyms><Name><Value>sphingosine-1-phosphate receptor-1 agonist (immunological disorder), Actelion</Value></Name><Name><Value>S1P1 agonist (immunological disorder), Actelion</Value></Name><Name><Value>S1P1 modulator (immunological disorder), Actelion</Value></Name><Name><Value>cenerimod</Value><Types><Type>INN</Type></Types></Name><Name><Value>ACT-334441</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1262414-04-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23780">Actelion Ltd</CompanyOriginator><CompaniesPrimary><Company id="1149835">Idorsia Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="23780">Actelion Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="72574" type="Drug"><TargetEntity id="673543" type="siDrug"></TargetEntity><TargetEntity id="673413" type="siDrug"></TargetEntity><TargetEntity id="673392" type="siDrug"></TargetEntity><TargetEntity id="721189" type="siDrug"></TargetEntity><TargetEntity id="673521" type="siDrug"></TargetEntity><TargetEntity id="673540" type="siDrug"></TargetEntity><TargetEntity id="721186" type="siDrug"></TargetEntity><TargetEntity id="673404" type="siDrug"></TargetEntity><TargetEntity id="654573" type="siDrug"></TargetEntity><TargetEntity id="673546" type="siDrug"></TargetEntity><TargetEntity id="721175" type="siDrug"></TargetEntity><TargetEntity id="673401" type="siDrug"></TargetEntity><TargetEntity id="673537" type="siDrug"></TargetEntity><TargetEntity id="721173" type="siDrug"></TargetEntity><TargetEntity id="673457" type="siDrug"></TargetEntity><TargetEntity id="673394" type="siDrug"></TargetEntity><TargetEntity id="673452" type="siDrug"></TargetEntity><TargetEntity id="721182" type="siDrug"></TargetEntity><TargetEntity id="721169" type="siDrug"></TargetEntity><TargetEntity id="721185" type="siDrug"></TargetEntity><TargetEntity id="673398" type="siDrug"></TargetEntity><TargetEntity id="673511" type="siDrug"></TargetEntity><TargetEntity id="673519" type="siDrug"></TargetEntity><TargetEntity id="673456" type="siDrug"></TargetEntity><TargetEntity id="721187" type="siDrug"></TargetEntity><TargetEntity id="721167" type="siDrug">Cenerimod</TargetEntity><TargetEntity id="431925" type="siDrug">Ponesimod</TargetEntity><TargetEntity id="673545" type="siDrug"></TargetEntity><TargetEntity id="673458" type="siDrug"></TargetEntity><TargetEntity id="673518" type="siDrug"></TargetEntity><TargetEntity id="673454" type="siDrug"></TargetEntity><TargetEntity id="673395" type="siDrug"></TargetEntity><TargetEntity id="673513" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1149835" type="Company"><TargetEntity id="5056400072" type="organizationId">Idorsia Ltd</TargetEntity></SourceEntity><SourceEntity id="23780" type="Company"><TargetEntity id="4295890901" type="organizationId">Actelion Ltd</TargetEntity></SourceEntity><SourceEntity id="185" type="ciIndication"><TargetEntity id="10021428" type="MEDDRA"/><TargetEntity id="D007154" type="MeSH"/><TargetEntity id="-155407498" type="omicsDisease"/><TargetEntity id="1128" type="siCondition"/></SourceEntity><SourceEntity id="318" type="ciIndication"><TargetEntity id="M32" type="ICD10"/><TargetEntity id="10042945" type="MEDDRA"/><TargetEntity id="D008180" type="MeSH"/><TargetEntity id="-1461472531" type="omicsDisease"/><TargetEntity id="731" type="siCondition"/></SourceEntity><SourceEntity id="8518" type="Action"><TargetEntity id="2107" type="Mechanism">Lysophospholipid edg1 (S1P1) Receptor Ligands</TargetEntity></SourceEntity><SourceEntity id="PTGT-02045" type="ciTarget"><TargetEntity id="146312404319013" type="siTarget">Sphingosine 1-phosphate receptor 1</TargetEntity><TargetEntity id="-1055719420" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="185">Immune disorder</Indication><Indication id="318">Systemic lupus erythematosus</Indication></IndicationsPrimary><ActionsPrimary><Action id="8518">Sphingosine-1-phosphate receptor-1 modulator</Action></ActionsPrimary><ActionsSecondary><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-05-08T07:58:45.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>2011-07-18T16:27:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1149835" linkType="Company"&gt;Idorsia&lt;/ulink&gt;, a spin off of &lt;ulink linkID="23780" linkType="Company"&gt;Actelion&lt;/ulink&gt;, is developing a sphingosine-1-phosphate receptor-1 (S1P1) modulator, cenerimod (ACT-334441), for the potential oral treatment of immunological disorders including systemic lupus erythematosus (SLE)  [&lt;ulink linkID="1208227" linkType="Reference"&gt;1208227&lt;/ulink&gt;], [&lt;ulink linkID="1383784" linkType="Reference"&gt;1383784&lt;/ulink&gt;], [&lt;ulink linkID="1651315" linkType="Reference"&gt;1651315&lt;/ulink&gt;], [&lt;ulink linkID="1658759" linkType="Reference"&gt;1658759&lt;/ulink&gt;],   [&lt;ulink linkID="1671991" linkType="Reference"&gt;1671991&lt;/ulink&gt;], [&lt;ulink linkID="1677050" linkType="Reference"&gt;1677050&lt;/ulink&gt;], [&lt;ulink linkID="1938314" linkType="Reference"&gt;1938314&lt;/ulink&gt;].  In April 2015,   the drug was listed as being in phase II development for  SLE [&lt;ulink linkID="1652216" linkType="Reference"&gt;1652216&lt;/ulink&gt;] and in June 2015 a phase II trial was initiated [&lt;ulink linkID="1671991" linkType="Reference"&gt;1671991&lt;/ulink&gt;]; in December 2018, phase II studies were ongoing [&lt;ulink linkID="2108497" linkType="Reference"&gt;2108497&lt;/ulink&gt;]. In November 2012, Actelion was seeking to outlicense the program [&lt;ulink linkID="1341027" linkType="Reference"&gt;1341027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Actelion is also developing  the  S1P1 agonist &lt;ulink linkID="53974" linkType="Drug"&gt;ponesimod&lt;/ulink&gt; for the potential treatment of autoimmune diseases. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In May 2019, Idorsia was developing the product as a class 1 chemical drug in China  [&lt;ulink linkID="2148060" linkType="Reference"&gt;2148060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, the US FDA granted cenerimod Fast Track status for the treatment of SLE [&lt;ulink linkID="2002733" linkType="Reference"&gt;2002733&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2019, an IND was filed in China [&lt;ulink linkID="2148060" linkType="Reference"&gt;2148060&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, the first patient was enrolled in a multicenter, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose phase IIb study (&lt;ulink linkID="360217" linkType="Protocol"&gt;NCT03742037&lt;/ulink&gt;; ID-064A202; 2018-001808-11) in the US, Europe, Israel, Taiwan, Mexico and Thailand  to evaluate the efficacy and safety of cenerimod, in adult patients (expected n = 500) with   moderately to severely active, autoantibody-positive SLE. Patients would receive cenerimod in addition to background SLE therapy. The primary endpoint  was to  evaluate the change from the baseline  in the modified SLE disease activity index (mSLEDAI) for up to 6 months. At that time, the trial was expected to be completed in September  2021 [&lt;ulink linkID="2108497" linkType="Reference"&gt;2108497&lt;/ulink&gt;], [&lt;ulink linkID="2117925" linkType="Reference"&gt;2117925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, a prospective, multicenter, multinational, randomized, double-blind, placebo-controlled, dose-response phase II trial was planned to be initiated in patients (expected n = 64) with systemic lupus erythematosus. At that time, the company expected to complete the trial in 20 months [&lt;ulink linkID="1651315" linkType="Reference"&gt;1651315&lt;/ulink&gt;]. In June 2015, the multicenter, dose-response phase I/II study (&lt;ulink linkID="232164" linkType="Protocol"&gt;NCT02472795&lt;/ulink&gt;; AC-064A201) in patients with SLE (n = 64) was initiated in Georgia. The study was planned in the US, Belarus, Bulgaria, Russian Federation and Ukraine. At that time, the study was expected to complete in January 2017; in June 2015, the trial was recruiting in the US [&lt;ulink linkID="1671991" linkType="Reference"&gt;1671991&lt;/ulink&gt;]. By April 2016, the trial was listed as a phase II study. The study completed in February 2017  [&lt;ulink linkID="1671991" linkType="Reference"&gt;1671991&lt;/ulink&gt;]. In January 2019, data were reported. Data demonstrated that the drug induced a dose-dependent, sustained reduction in circulating lymphocyte counts that was reversible after treatment discontinuation. The drug was found to be well tolerated at all dose levels [&lt;ulink linkID="2108497" linkType="Reference"&gt;2108497&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, clinical data from a double-blind, placebo-controlled study which evaluated the pharmacokinetics, pharmacodynamics and tolerability of multiple-dose administration of cenerimod in 8 healthy male subjects were presented at the 2016 Annual Meeting of the ACCP in Bethesda, MD. Subjects were randomized (3:1) to receive cenerimod (0.5, 1, 2 or 4 mg) or placebo for 35 days. The Tmax of cenerimod was 5 to 6 h and 4.3 to 6 h on days 1 and 35, respectively. At 0.5, 1, 2 and 4 mg doses, the terminal half life after last cenerimod administration was 283, 436, 415 and 539 h, respectively. The lymphocyte count was not altered with placebo, but dose dependent decrease in the lymphocyte count was observed following initiation of cenerimod treatment and reached a plateau after 20 to 23 days with a reduction of approximately 34, 50, 64 and 60% with 0.5, 1, 2 and 4 mg doses, respectively. Cenerimod was generally well-tolerated and the adverse events reported were of mild to moderate intensity [&lt;ulink linkID="1894937" linkType="Reference"&gt;1894937&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In 2006, clinical studies began. In July 2011, the drug was listed as being in phase I development [&lt;ulink linkID="1208227" linkType="Reference"&gt;1208227&lt;/ulink&gt;]; in March 2014, this was still the case  [&lt;ulink linkID="1536094" linkType="Reference"&gt;1536094&lt;/ulink&gt;]. In September 2016, a single-center, open-label, phase I trial (NCT02914223; AC-064-103) to investigate the mass balance, pharmacokinetics, and metabolism following single po administration of 14C-radiolabeled cenerimod was initiated in healthy male subjects (n = 6) in the Netherlands. In January 2017, the trial was completed [&lt;ulink linkID="1895180" linkType="Reference"&gt;1895180&lt;/ulink&gt;]. In Janaury 2019, results reported that the drug had marked and sustained circulating lymphocyte lowering effects [&lt;ulink linkID="2108497" linkType="Reference"&gt;2108497&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-12-21T00:00:00.000Z</StatusDate><Source id="2117925" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-12-21T00:00:00.000Z</StatusDate><Source id="2117925" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-12-21T00:00:00.000Z</StatusDate><Source id="2117925" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2018-12-21T00:00:00.000Z</StatusDate><Source id="2117925" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="185">Immune disorder</Indication><StatusDate>2017-06-16T00:00:00.000Z</StatusDate><Source id="1938314" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1149835">Idorsia Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2019-05-08T00:00:00.000Z</StatusDate><Source id="2148060" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2017-06-16T00:00:00.000Z</StatusDate><Source id="1671991" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="185">Immune disorder</Indication><StatusDate>2011-07-19T00:00:00.000Z</StatusDate><Source id="1208227" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2015-06-12T00:00:00.000Z</StatusDate><Source id="1671991" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="318">Systemic lupus erythematosus</Indication><StatusDate>2015-06-12T00:00:00.000Z</StatusDate><Source id="1671991" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23780">Actelion Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="185">Immune disorder</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="1208227" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1149835">Idorsia Ltd</OwnerCompany><Country id="US">US</Country><Indication id="318">Systemic lupus erythematosus</Indication><AwardedIndication>Systemic lupus erythematosus</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-12-31T00:00:00.000Z</MileStoneDate><Source id="2002733" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-02045"><Name>Sphingosine-1-phosphate receptor-1</Name><SwissprotNumbers><Swissprot>O08530</Swissprot><Swissprot>P21453</Swissprot><Swissprot>P48303</Swissprot><Swissprot>Q9DDK4</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2148060" linkType="reference" linkID="2148060"&gt;2148060&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1149835">Idorsia Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCc1cc(cc(c1OC[C@H](CO)O)C)c2nc(on2)c3cc(nc(c3)OC)C4CCCC4</Smiles></StructureSmiles><Deals><Deal id="244375" title="Actelion to spin-out its drug discovery operations into new Swiss company, Idorsia "/></Deals><PatentFamilies><PatentFamily id="223297" number="WO-2011007324" title="Pyridin-4-yl derivatives"/><PatentFamily id="2641215" number="WO-2013175397" title="New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>